SLIT is a feasible option for classical subcutaneous immunotherapy to treat respiratory allergy. It is increasingly prescribed in Europe. The lack of reimbursement may limit its prescription. The 5-grass pollen tablets were authorized by the EMA to treat grass-pollen induced rhinitis and were approved in Italy for full reimbursement. This study was done with the purpose to evaluate the opinions of allergy specialists after the availability of the reimbursed 5-grass pollen tablets.

A multiple-choice questionnaire composed of six questions. This questionnaire was used to assess the specialist’s opinion. The questionnaire was uploaded on the free access online platform. The link to access the platform was sent to all members of the SIAAIC. In the ending, the access was closed and data was downloaded directly from the website.

The study concluded through its findings that the majority of allergists felt as most important the concept of SLIT as a drug. Mainly the content of allergen extract mirroring the natural exposure, the pre-coseasonal schedule as the most patient’s oriented, the very good profile of tolerability and safety were important factors.